Kevin Kalinsky, MD, MS

Articles

Antibody-Drug Conjugates in Lung Cancer

October 27th 2023

A medical oncologist reviews the antibody-drug conjugate landscape in lung cancer.

Toxicity Management for T-DM1 and T-DXd in Breast Cancer

October 20th 2023

Specialists in breast cancer review toxicity management practices for T-DM1 and trastuzumab deruxtecan [T-DXd].

Antibody-Drug Conjugates in Breast Cancer

October 20th 2023

A breast medical oncologist provides insights on antibody-drug conjugates in the breast cancer space and discusses ongoing research.

Best Practices for Patient Education Surrounding Cancer Treatment

October 13th 2023

The expert panel has a comprehensive discussion about best practices for patient education and the barriers to effective testing.

Molecular Testing Considerations in Cancer Treatment

October 13th 2023

Medical oncologists review the complexities of molecular testing, including tissue exhaustion, and discuss management approaches.

Biomarker Testing in Gastrointestinal and Lung Cancers

October 6th 2023

Comprehensive insights on biomarker testing practices for patients with lung or gastrointestinal cancers.

Molecular Testing in Breast Cancer

October 6th 2023

A breast medical oncologist and nurse practitioner review molecular testing practices for patients with breast cancer.

Mechanisms of Action of Antibody-Drug Conjugates

September 29th 2023

The expert panel discusses the history of antibody-drug conjugates and explores their mechanisms of action.

Overview of Antibody-Drug Conjugates (ADCs)

September 29th 2023

A panel of cancer-treating specialists introduce the discussion with a broad overview of antibody-drug conjugates (ADCs).

HER2+ Breast Cancer With CNS or Leptomeningeal Metastases: Future Directions in Care

May 29th 2023

Closing out his review of therapy for HER2+ metastatic breast cancer, Kevin Kalinsky, MD, MS, looks toward future evolutions in the treatment landscape.

Role of T-DXd in Patients With HER2+ Metastatic Breast Cancer and CNS Metastasis

May 22nd 2023

A brief discussion on the role of trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer who progress on tucatinib therapy.

HER2+ Metastatic Breast Cancer: Factors in Selecting 2L Therapy and Beyond

May 22nd 2023

A key opinion leader in HER2+ metastatic breast cancer shares his perspective on key factors in selecting second or later-line therapy.

HER2+ Metastatic Breast Cancer: An Evolving Treatment Armamentarium

May 15th 2023

Comprehensive insight on the treatment armamentarium currently available to patients with HER2+ metastatic breast cancer and CNS disease.

Landscape of HER2+ Metastatic Breast Cancer: Patient Overview

May 15th 2023

Expert oncologist Kevin Kalinsky, MD, MS, reviews a patient case of HER2+ metastatic breast cancer and highlights key findings in this disease setting.

Dr Kalinsky on Differences in Efficacy Between CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

May 1st 2023

Kevin Kalinsky, MD, MS, discusses differences in efficacy data for CDK4/6 inhibitors in the treatment of patients with metastatic hormone receptor–positive/HER2-negative breast cancer.

Dr. Kalinsky on the Importance of Molecular Profiling in Breast Cancer

October 25th 2022

Kevin Kalinsky, MD, MS, discusses the importance of molecular profiling in breast cancer.

Dr. Kalinsky on Ovarian Function Suppression and Chemotherapy in HR–Positive Breast Cancer

July 14th 2022

Kevin Kalinsky, MD, MS, discusses the relationship between ovarian function suppression and chemotherapy benefits in premenopausal patients with HR–positive breast cancer.

Dr. Kalinsky on Updates from the TAILORx Trial in HR-Positive/HER2-Negative Breast Cancer

May 4th 2022

Kevin Kalinsky, MD, MS, discusses updates from the phase 3 TAILORx trial in patients with hormone receptor–positive or HER2-negative breast cancer with node-negative disease.

Dr. Kalinsky on Strategies to Prevent Recurrence in Early Breast Cancer

April 26th 2022

Kevin Kalinsky, MD, MS, discusses the potential benefits of chemotherapy in preventing disease recurrence in premenopausal patients with breast cancer.

SABCS 2021 Updates in Key Clinical Trials for Breast Cancer

February 14th 2022

Patrick Neven MD, PhD; Sara A. Hurvitz, MD; Kevin Kalinsky, MD, MS; and Aditya Bardia, MD, MPH, share insight on updates in key clinical trials and novel therapies in breast cancer presented at SABCS 2021.